Beckman Coulter, Inc.
Beckman Coulter – SARS-CoV-2 Assays
The Access SARS-CoV-2 Assays are qualitative immunoassay tests that detect IgG or IgM antibodies. Both the IgM and IgG assays can identify antibodies even in asymptomatic individuals can be used to provide clinicians with useful information.
Access SARS-CoV-2 IgG
· The test has a confirmed 100 % Positive Agreement (sensitivity) at 18 days post PCR confirmed positive test and 99.6 % Negative Agreement (specificity)
Access SARS-CoV-2 IgM
· The test has confirmed 98.3 % positive percent agreement (sensitivity) at 15-30 days post symptom onset and 99.9 % negative percent agreement (specificity)